[
  {
    "ts": null,
    "headline": "Dow Closes Above 44,000 for First Time; S&P 500 Tops 6,000 as Tesla Soars",
    "summary": "Dow Closes Above 44,000 for First Time; S&P 500 Tops 6,000 as Tesla Soars",
    "url": "https://finnhub.io/api/news?id=7000085feb7eddb1ac1dc9b060e7e7c736af11c33fdc3fc6cf762dbf81feba52",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731362353,
      "headline": "Dow Closes Above 44,000 for First Time; S&P 500 Tops 6,000 as Tesla Soars",
      "id": 131292799,
      "image": "https://media.zenfs.com/en/mt_newswires_premium_news_706/0c887a492733aab96ac405a5871f559a",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Dow Closes Above 44,000 for First Time; S&P 500 Tops 6,000 as Tesla Soars",
      "url": "https://finnhub.io/api/news?id=7000085feb7eddb1ac1dc9b060e7e7c736af11c33fdc3fc6cf762dbf81feba52"
    }
  },
  {
    "ts": null,
    "headline": "Dow Closes Above 44,000 for First Time; S&P 500 Tops 6,000",
    "summary": "Dow Closes Above 44,000 for First Time; S&P 500 Tops 6,000",
    "url": "https://finnhub.io/api/news?id=8122c88285b7967a60006d0ac3818bf4838c0c32b18ab575fd61a1971e5fdae7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731360953,
      "headline": "Dow Closes Above 44,000 for First Time; S&P 500 Tops 6,000",
      "id": 131292802,
      "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Dow Closes Above 44,000 for First Time; S&P 500 Tops 6,000",
      "url": "https://finnhub.io/api/news?id=8122c88285b7967a60006d0ac3818bf4838c0c32b18ab575fd61a1971e5fdae7"
    }
  },
  {
    "ts": null,
    "headline": "S&P 500 Gains and Losses Today: Index Closes Above 6,000 on Post-Election Rally",
    "summary": "The S&P 500 added 0.1% on Monday, Nov. 11, 2024, closing above the 6,000-point milestone as investors continued to weigh the implications of the election.",
    "url": "https://finnhub.io/api/news?id=5047594a12af882586b50c8407717de3dc9085d5a71ccab5335413f0e01523ca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731360757,
      "headline": "S&P 500 Gains and Losses Today: Index Closes Above 6,000 on Post-Election Rally",
      "id": 131292537,
      "image": "https://www.investopedia.com/thmb/nShOzNhv-JIfWfZpNBMmaE470YQ=/1500x0/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-2182210425-a0e52d2df1fd4cabba9fad3985075b17.jpg",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The S&P 500 added 0.1% on Monday, Nov. 11, 2024, closing above the 6,000-point milestone as investors continued to weigh the implications of the election.",
      "url": "https://finnhub.io/api/news?id=5047594a12af882586b50c8407717de3dc9085d5a71ccab5335413f0e01523ca"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie tumbles on drug test disappointment, Bristol-Myers gains",
    "summary": "AbbVie (ABBV) shares slide after its schizophrenia drug failed to meet the goals of its mid-stage trial. Shares of Bristol-Myers Squibb (BMY), a competitor which makes a similar drug, have jumped. Market Domination Hosts Julie Hyman and Josh Lipton outline what investors need to know. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. This post was written by Naomi Buchanan.",
    "url": "https://finnhub.io/api/news?id=f187fb376e4dbbaf610b7babf95f352644c8762c3e84b3084a27c7871b5d8ab0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731357937,
      "headline": "AbbVie tumbles on drug test disappointment, Bristol-Myers gains",
      "id": 131292299,
      "image": "https://s.yimg.com/ny/api/res/1.2/xk9OudErYJqsN1gk_gSl6w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzY-/https://s.yimg.com/os/creatr-uploaded-images/2024-10/8b2797a0-a06a-11ef-baed-fe04858da93c",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (ABBV) shares slide after its schizophrenia drug failed to meet the goals of its mid-stage trial. Shares of Bristol-Myers Squibb (BMY), a competitor which makes a similar drug, have jumped. Market Domination Hosts Julie Hyman and Josh Lipton outline what investors need to know. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. This post was written by Naomi Buchanan.",
      "url": "https://finnhub.io/api/news?id=f187fb376e4dbbaf610b7babf95f352644c8762c3e84b3084a27c7871b5d8ab0"
    }
  },
  {
    "ts": null,
    "headline": "Why AbbVie Stock Was Getting Mashed on Monday",
    "summary": "A splashy recent acquisition by the company might not be panning out.",
    "url": "https://finnhub.io/api/news?id=29355e0240cdcc06598bea09f080e650005f70d9beb752880189edac3a6db34f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731356566,
      "headline": "Why AbbVie Stock Was Getting Mashed on Monday",
      "id": 131294142,
      "image": "https://g.foolcdn.com/editorial/images/797456/person-in-a-lab-gazing-into-a-microscope.jpg",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "A splashy recent acquisition by the company might not be panning out.",
      "url": "https://finnhub.io/api/news?id=29355e0240cdcc06598bea09f080e650005f70d9beb752880189edac3a6db34f"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie And Pfizer: Q3 Dividend Checkup Post-Earnings",
    "summary": "AbbVie and Pfizer recently released earnings. Read how dividend investors should now view these healthcare giants after reporting their numbers.",
    "url": "https://finnhub.io/api/news?id=4f4aed935ada37d5e45a05362862ee1e37a6309d9f3c069c69991b449b2f4877",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731350729,
      "headline": "AbbVie And Pfizer: Q3 Dividend Checkup Post-Earnings",
      "id": 131293127,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/172846513/image_172846513.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "AbbVie and Pfizer recently released earnings. Read how dividend investors should now view these healthcare giants after reporting their numbers.",
      "url": "https://finnhub.io/api/news?id=4f4aed935ada37d5e45a05362862ee1e37a6309d9f3c069c69991b449b2f4877"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie's Emraclidine For Schizophrenia 'Surprisingly Disappoints,' Analyst Says Pipeline Is Underappreciated",
    "summary": "On Monday, AbbVie Inc (NYSE:ABBV) stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia failed two Phase 2 trials. The studies did not meet their primary endpoint of showing a statistically significant improvement in the change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score compared to the placebo group at week 6. PANSS is a scale used for measuring the symptom severity of schizophrenia. A",
    "url": "https://finnhub.io/api/news?id=c9169366a07ed478c83ca1928be43456c0e096ef8aadecdb7e5bb5f90b1ebbb7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731347516,
      "headline": "AbbVie's Emraclidine For Schizophrenia 'Surprisingly Disappoints,' Analyst Says Pipeline Is Underappreciated",
      "id": 131288224,
      "image": "https://media.zenfs.com/en/Benzinga/64c70f9e718797913b39eed875bdfeac",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "On Monday, AbbVie Inc (NYSE:ABBV) stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia failed two Phase 2 trials. The studies did not meet their primary endpoint of showing a statistically significant improvement in the change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score compared to the placebo group at week 6. PANSS is a scale used for measuring the symptom severity of schizophrenia. A",
      "url": "https://finnhub.io/api/news?id=c9169366a07ed478c83ca1928be43456c0e096ef8aadecdb7e5bb5f90b1ebbb7"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Down as AbbVie, Humana Weigh -- Health Care Roundup",
    "summary": "Health-care companies declined as concerns about AbbVie and Humana weighed. Shares of AbbVie plunged, losing more than 12% of their value after the drugmaker said participants in two mid-stage...",
    "url": "https://finnhub.io/api/news?id=4cfe1820b43100d52a6955d9d732865c6d0ce7a61ac29141a5b557f25a23bb54",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731346809,
      "headline": "Health Care Down as AbbVie, Humana Weigh -- Health Care Roundup",
      "id": 131292204,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "Health-care companies declined as concerns about AbbVie and Humana weighed. Shares of AbbVie plunged, losing more than 12% of their value after the drugmaker said participants in two mid-stage...",
      "url": "https://finnhub.io/api/news?id=4cfe1820b43100d52a6955d9d732865c6d0ce7a61ac29141a5b557f25a23bb54"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Stock Sinks After Schizophrenia Drug Trials Disappoint",
    "summary": "Shares of AbbVie plummeted Monday after the company said its schizophrenia drug Emraclidine missed key goals in a pair of trials.",
    "url": "https://finnhub.io/api/news?id=de6b158fbf81d2149cfa73df997524b97838cc663d755e529ed9c3794f7c133d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731345512,
      "headline": "AbbVie Stock Sinks After Schizophrenia Drug Trials Disappoint",
      "id": 131294144,
      "image": "https://www.investopedia.com/thmb/1uMmEvMuPuVPhD-BtI7GlCLn9Zg=/1500x0/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-2172784450-f3019c75fc0a4b74954a38833c0a69ca.jpg",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Shares of AbbVie plummeted Monday after the company said its schizophrenia drug Emraclidine missed key goals in a pair of trials.",
      "url": "https://finnhub.io/api/news?id=de6b158fbf81d2149cfa73df997524b97838cc663d755e529ed9c3794f7c133d"
    }
  },
  {
    "ts": null,
    "headline": "Top Stock Movers Now: Tesla, Robinhood Markets, MicroStrategy, and More",
    "summary": "U.S. equities continued their post-election rally at midday, fueled by optimism that the new Trump administration will be a positive for the markets.",
    "url": "https://finnhub.io/api/news?id=a99ebb726af9e211ad32bd95e5a1431b116a8ba6eda1f94d4fb12b570dec6720",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731344697,
      "headline": "Top Stock Movers Now: Tesla, Robinhood Markets, MicroStrategy, and More",
      "id": 131294145,
      "image": "https://www.investopedia.com/thmb/0C5UYPOjsVmkQlFF1C7w3TqcxJ8=/1500x0/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-2182410725-7ddac77723a843638f3afa20d60257c8.jpg",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "U.S. equities continued their post-election rally at midday, fueled by optimism that the new Trump administration will be a positive for the markets.",
      "url": "https://finnhub.io/api/news?id=a99ebb726af9e211ad32bd95e5a1431b116a8ba6eda1f94d4fb12b570dec6720"
    }
  },
  {
    "ts": null,
    "headline": "Is AbbVie Still A Strong Buy After Fantastic Gains? (Rating Downgrade)",
    "summary": "Discover how AbbVie investors that bought the anxiety over the loss of Humira exclusivity are sitting on massive gains. Read more here.",
    "url": "https://finnhub.io/api/news?id=e127d456e52523809bb48e20697f3ee1eef00b6bade7b26393f8be47387d6613",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731344400,
      "headline": "Is AbbVie Still A Strong Buy After Fantastic Gains? (Rating Downgrade)",
      "id": 131291634,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1385800864/image_1385800864.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Discover how AbbVie investors that bought the anxiety over the loss of Humira exclusivity are sitting on massive gains. Read more here.",
      "url": "https://finnhub.io/api/news?id=e127d456e52523809bb48e20697f3ee1eef00b6bade7b26393f8be47387d6613"
    }
  },
  {
    "ts": null,
    "headline": "Top Midday Stories: Cigna Won't Pursue Combination With Humana; AbbVie Phase 2 Schizophrenia Drug Trials Fail to Meet Primary Endpoints",
    "summary": "Top Midday Stories: Cigna Won't Pursue Combination With Humana; AbbVie Phase 2 Schizophrenia Drug Trials Fail to Meet Primary Endpoints",
    "url": "https://finnhub.io/api/news?id=3f09d76158fac16479f95fe9fb048c07877fca762818bc476b758d40c1cf5534",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731342926,
      "headline": "Top Midday Stories: Cigna Won't Pursue Combination With Humana; AbbVie Phase 2 Schizophrenia Drug Trials Fail to Meet Primary Endpoints",
      "id": 131287933,
      "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Top Midday Stories: Cigna Won't Pursue Combination With Humana; AbbVie Phase 2 Schizophrenia Drug Trials Fail to Meet Primary Endpoints",
      "url": "https://finnhub.io/api/news?id=3f09d76158fac16479f95fe9fb048c07877fca762818bc476b758d40c1cf5534"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. stock underperforms Monday when compared to competitors",
    "summary": "AbbVie Inc. stock underperforms Monday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=fdbce2af156fdede73643543ecb3b109a9527287e2751e85f4c685c3e68d631d",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731342900,
      "headline": "AbbVie Inc. stock underperforms Monday when compared to competitors",
      "id": 131414145,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock underperforms Monday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=fdbce2af156fdede73643543ecb3b109a9527287e2751e85f4c685c3e68d631d"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Rockets 11% As Investors Question AbbVie's $8.7 Billion 'Mistake'",
    "summary": "Bristol Myers Squibb stock rocketed Monday after AbbVie's experimental schizophrenia treatment failed in a pair of midstage studies.",
    "url": "https://finnhub.io/api/news?id=11bf0d0ac31355a22d9f2e26aec905187c2805243413bef511b34506b5ef54ee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731342803,
      "headline": "Bristol Rockets 11% As Investors Question AbbVie's $8.7 Billion 'Mistake'",
      "id": 131286640,
      "image": "",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Bristol Myers Squibb stock rocketed Monday after AbbVie's experimental schizophrenia treatment failed in a pair of midstage studies.",
      "url": "https://finnhub.io/api/news?id=11bf0d0ac31355a22d9f2e26aec905187c2805243413bef511b34506b5ef54ee"
    }
  },
  {
    "ts": null,
    "headline": "These Stocks Moved the Most Today: Tesla, DJT, Coinbase, MARA, Cigna, Humana, AbbVie, Super Micro, and More",
    "summary": "These Stocks Moved the Most Today: Tesla, DJT, Coinbase, MARA, Cigna, Humana, AbbVie, Super Micro, and More",
    "url": "https://finnhub.io/api/news?id=38249936ca156e531ea8f3dd3e45304319675b96a43ca23336e3b13dce555ae1",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731341940,
      "headline": "These Stocks Moved the Most Today: Tesla, DJT, Coinbase, MARA, Cigna, Humana, AbbVie, Super Micro, and More",
      "id": 131414146,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "These Stocks Moved the Most Today: Tesla, DJT, Coinbase, MARA, Cigna, Humana, AbbVie, Super Micro, and More",
      "url": "https://finnhub.io/api/news?id=38249936ca156e531ea8f3dd3e45304319675b96a43ca23336e3b13dce555ae1"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Tumbles After New Schizophrenia Drug Fails Two Trials",
    "summary": "(Bloomberg) -- AbbVie Inc. shares fell the most in more than four years after two mid-stage trials of its drug to treat schizophrenia failed to meet their primary goal, a blow to the company’s $8.7 billion acquisition of Cerevel Therapeutics earlier this year.Most Read from BloombergThe Leaf Blowers Will Not Go QuietlyArizona Elections Signal Robust Immigration Enforcement Under TrumpScoring an Architectural Breakthrough in Denver’s RiNo DistrictKey Ballot Initiatives and Local Races Highlight V",
    "url": "https://finnhub.io/api/news?id=84e5a9bde4f7051b44c7cb824726301ad3e93454feae6c6d019fe159a6e50394",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731341806,
      "headline": "AbbVie Tumbles After New Schizophrenia Drug Fails Two Trials",
      "id": 131286641,
      "image": "https://s.yimg.com/ny/api/res/1.2/OhAJAmy_Kwsbq.U.y6a1nw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD03ODU-/https://media.zenfs.com/en/bloomberg_markets_842/645b82e294d38676c1149a17729b00dc",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "(Bloomberg) -- AbbVie Inc. shares fell the most in more than four years after two mid-stage trials of its drug to treat schizophrenia failed to meet their primary goal, a blow to the company’s $8.7 billion acquisition of Cerevel Therapeutics earlier this year.Most Read from BloombergThe Leaf Blowers Will Not Go QuietlyArizona Elections Signal Robust Immigration Enforcement Under TrumpScoring an Architectural Breakthrough in Denver’s RiNo DistrictKey Ballot Initiatives and Local Races Highlight V",
      "url": "https://finnhub.io/api/news?id=84e5a9bde4f7051b44c7cb824726301ad3e93454feae6c6d019fe159a6e50394"
    }
  },
  {
    "ts": null,
    "headline": "On Wall Street, ‘flat out’ failure of AbbVie schizophrenia drug leaves analysts stunned",
    "summary": "Negative drug results cost AbbVie billions of dollars in market value and convinced analysts that Bristol Myers had placed a better bet in buying Karuna Therapeutics.",
    "url": "https://finnhub.io/api/news?id=b9c38fb503b1f28212c7249ba5817363351ebd99c2270eed4d34bccde3e86507",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731341652,
      "headline": "On Wall Street, ‘flat out’ failure of AbbVie schizophrenia drug leaves analysts stunned",
      "id": 131294149,
      "image": "https://imgproxy.divecdn.com/1VkJByYLAsooqXJ6u2spJOeSb21aNeJte2QlVj9upgs/g:nowe:0:457/c:1333:753/rs:fit:770:435/bG9jYWw6Ly8vZGl2ZWltYWdlL0FiYlZpZV9CYXlfQXJlYV8wOTAyLmpwZw==.webp",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Negative drug results cost AbbVie billions of dollars in market value and convinced analysts that Bristol Myers had placed a better bet in buying Karuna Therapeutics.",
      "url": "https://finnhub.io/api/news?id=b9c38fb503b1f28212c7249ba5817363351ebd99c2270eed4d34bccde3e86507"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Stock: Keep Calm And Buy The Dip",
    "summary": "AbbVie saw a 10% drop after its drug emraclidine failed in trials. Find out why ABBV stock is struggling and how this affects its long-term prospects.",
    "url": "https://finnhub.io/api/news?id=c6e78a9560decbb94f958fde4698becf977b9e10e3e3163eb8f51e440b2b06a6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731340234,
      "headline": "AbbVie Stock: Keep Calm And Buy The Dip",
      "id": 131290912,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2175801616/image_2175801616.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "AbbVie saw a 10% drop after its drug emraclidine failed in trials. Find out why ABBV stock is struggling and how this affects its long-term prospects.",
      "url": "https://finnhub.io/api/news?id=c6e78a9560decbb94f958fde4698becf977b9e10e3e3163eb8f51e440b2b06a6"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies. Bristol Myers Jumps.",
    "summary": "Shares of  AbbVie  were getting hammered Monday after the drug maker said two Phase 2 trials of its experimental schizophrenia drug showed no significant improvement in symptoms.  The drug, emraclidine, didn’t meet its “primary endpoint of showing a statistically significant reduction (improvement)” on a widely used scale, compared to the placebo group at week six, according to a press release from the company.  The study examined patients who were experiencing acute exacerbation of psychotic symptoms.",
    "url": "https://finnhub.io/api/news?id=011c4f3cee24d94abdd07f2c602f8fc31e5425e85edbb0bab02f4e09cac04775",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731340020,
      "headline": "AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies. Bristol Myers Jumps.",
      "id": 131286377,
      "image": "https://s.yimg.com/ny/api/res/1.2/wIw1SYJSvVmuZxyb68GMZg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/Barrons.com/e6469760d530dff947ae3095e80a61aa",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Shares of  AbbVie  were getting hammered Monday after the drug maker said two Phase 2 trials of its experimental schizophrenia drug showed no significant improvement in symptoms.  The drug, emraclidine, didn’t meet its “primary endpoint of showing a statistically significant reduction (improvement)” on a widely used scale, compared to the placebo group at week six, according to a press release from the company.  The study examined patients who were experiencing acute exacerbation of psychotic symptoms.",
      "url": "https://finnhub.io/api/news?id=011c4f3cee24d94abdd07f2c602f8fc31e5425e85edbb0bab02f4e09cac04775"
    }
  },
  {
    "ts": null,
    "headline": "Trending : Bristol-Myers Squibb Shares Up on Setback for AbbVie Schizophrenia Drug",
    "summary": "1457 ET -- Bristol-Myers Squibb is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. Shares were recently up 11% after AbbVie...",
    "url": "https://finnhub.io/api/news?id=929b88502186f6619a733d5abb7e4e832f72d2c29da75dbbc834c2d77ed210e5",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731338052,
      "headline": "Trending : Bristol-Myers Squibb Shares Up on Setback for AbbVie Schizophrenia Drug",
      "id": 131290344,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "1457 ET -- Bristol-Myers Squibb is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. Shares were recently up 11% after AbbVie...",
      "url": "https://finnhub.io/api/news?id=929b88502186f6619a733d5abb7e4e832f72d2c29da75dbbc834c2d77ed210e5"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb’s stock soars after rival AbbVie reports disappointing schizophrenia-drug trial",
    "summary": "Bristol Myers Squibb’s stock soars after rival AbbVie reports disappointing schizophrenia-drug trial",
    "url": "https://finnhub.io/api/news?id=95544b6e5cc679023c3c27ee2ab7ee3dd8f67de4d693d92569204a1e2f1d6c6c",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731337740,
      "headline": "Bristol Myers Squibb’s stock soars after rival AbbVie reports disappointing schizophrenia-drug trial",
      "id": 131414147,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "Bristol Myers Squibb’s stock soars after rival AbbVie reports disappointing schizophrenia-drug trial",
      "url": "https://finnhub.io/api/news?id=95544b6e5cc679023c3c27ee2ab7ee3dd8f67de4d693d92569204a1e2f1d6c6c"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Stock Slides on Schizophrenia Drug Study Failure",
    "summary": "AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock sharply lower. Phase 2 studies for emraclidine failed to show a statistically significant improvement in symptoms after six weeks, the biopharmaceutical company said Monday.",
    "url": "https://finnhub.io/api/news?id=7bfbeca807ba61f68da682aea98f93e1d6076fb3f8426def77fbc20b3985d7a3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731335960,
      "headline": "AbbVie Stock Slides on Schizophrenia Drug Study Failure",
      "id": 131286379,
      "image": "https://s.yimg.com/ny/api/res/1.2/UvgsJ1xjhB7u4X.YMCVoAA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/wsj.com/7c682c3888a014bf4f80de294a8db9b9",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock sharply lower. Phase 2 studies for emraclidine failed to show a statistically significant improvement in symptoms after six weeks, the biopharmaceutical company said Monday.",
      "url": "https://finnhub.io/api/news?id=7bfbeca807ba61f68da682aea98f93e1d6076fb3f8426def77fbc20b3985d7a3"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie shares slip after schizophrenia drug trial misses primary endpoint",
    "summary": "Investing.com - AbbVie (NYSE:ABBV) has announced that its two phase 2 trials of a treatment for adults with schizophrenia missed its primary endpoint, sending shares in the drugmaker down sharply in premarket US trading.",
    "url": "https://finnhub.io/api/news?id=fc5fc287e2a9656aacedd378e05a86e041c393c8853f44203448205e126668f1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731334670,
      "headline": "AbbVie shares slip after schizophrenia drug trial misses primary endpoint",
      "id": 131286381,
      "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Investing.com - AbbVie (NYSE:ABBV) has announced that its two phase 2 trials of a treatment for adults with schizophrenia missed its primary endpoint, sending shares in the drugmaker down sharply in premarket US trading.",
      "url": "https://finnhub.io/api/news?id=fc5fc287e2a9656aacedd378e05a86e041c393c8853f44203448205e126668f1"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Provides Update on Phase 2 Results for Emraclidine in Schizophrenia",
    "summary": "AbbVie (NYSE: ABBV) today announced that its two Phase 2 EMPOWER trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia who are experiencing an acute exacerbation of psychotic symptoms, did not meet their primary endpoint of showing a statistically significant reduction (improvement) in the change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score compared to the placebo group at week 6.",
    "url": "https://finnhub.io/api/news?id=8e53ee62cfe6cd157f847e4511212452f1e74ace4b0bda878f6ab88a3db7642a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731331800,
      "headline": "AbbVie Provides Update on Phase 2 Results for Emraclidine in Schizophrenia",
      "id": 131286646,
      "image": "https://media.zenfs.com/en/prnewswire.com/7466658ae46d58ba676379394c7ac42c",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) today announced that its two Phase 2 EMPOWER trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia who are experiencing an acute exacerbation of psychotic symptoms, did not meet their primary endpoint of showing a statistically significant reduction (improvement) in the change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score compared to the placebo group at week 6.",
      "url": "https://finnhub.io/api/news?id=8e53ee62cfe6cd157f847e4511212452f1e74ace4b0bda878f6ab88a3db7642a"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie: Emraclidine's Failure Eliminates An Important Growth Driver",
    "summary": "AbbVie's emraclidine setback in phase 2 trials impacts neuroscience pipeline, benefitting Bristol Myers Squibb's Cobenfy in muscarinic drug class. Learn more on ABBV stock here.",
    "url": "https://finnhub.io/api/news?id=c039e5d2d8a619182815b5454087e3a92e1987c15e340bdf9dbe24ae4a4a2e7f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731325754,
      "headline": "AbbVie: Emraclidine's Failure Eliminates An Important Growth Driver",
      "id": 131286787,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1726514483/image_1726514483.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "AbbVie's emraclidine setback in phase 2 trials impacts neuroscience pipeline, benefitting Bristol Myers Squibb's Cobenfy in muscarinic drug class. Learn more on ABBV stock here.",
      "url": "https://finnhub.io/api/news?id=c039e5d2d8a619182815b5454087e3a92e1987c15e340bdf9dbe24ae4a4a2e7f"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie’s $9B bet collapses as closely watched schizophrenia drug fails studies",
    "summary": "Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two Phase 2 trials.",
    "url": "https://finnhub.io/api/news?id=a79e6f1e9530a1b67b605fcd89472433b685a3a5580c2e87dc4e60aa82c73d34",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731325500,
      "headline": "AbbVie’s $9B bet collapses as closely watched schizophrenia drug fails studies",
      "id": 131288234,
      "image": "https://imgproxy.divecdn.com/o3rQRIkPk1DZsOCoe7Z26lDhYDdnd60L-p1a4qmgADs/g:nowe:0:106/c:2000:1129/rs:fit:770:435/bG9jYWw6Ly8vZGl2ZWltYWdlL0FiYlZpZV9CYXlfQXJlYV8wNTYxLmpwZw==.webp",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two Phase 2 trials.",
      "url": "https://finnhub.io/api/news?id=a79e6f1e9530a1b67b605fcd89472433b685a3a5580c2e87dc4e60aa82c73d34"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Shares Slide, Bristol Myers Shares Rise After Schizophrenia Study Setback -- Update",
    "summary": "By Colin Kellaher AbbVie said the schizophrenia drug candidate at the center of its recent $8.7 billion acquisition of Cerevel failed in a pair of mid-stage studies, sending the biopharmaceutical...",
    "url": "https://finnhub.io/api/news?id=060be4528ece7474f95a73d5f693d020a830bb9bde9c9a287da61102e6698548",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731321863,
      "headline": "AbbVie Shares Slide, Bristol Myers Shares Rise After Schizophrenia Study Setback -- Update",
      "id": 131285919,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "By Colin Kellaher AbbVie said the schizophrenia drug candidate at the center of its recent $8.7 billion acquisition of Cerevel failed in a pair of mid-stage studies, sending the biopharmaceutical...",
      "url": "https://finnhub.io/api/news?id=060be4528ece7474f95a73d5f693d020a830bb9bde9c9a287da61102e6698548"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Shares Slide, Bristol Myers Shares Rise After Schizophrenia Study Setback",
    "summary": "By Colin Kellaher AbbVie said the schizophrenia drug candidate at the center of its recent $8.7 billion acquisition of Cerevel failed in a pair of mid-stage studies, sending the biopharmaceutical...",
    "url": "https://finnhub.io/api/news?id=5a697cc03be339764aacd9e391e2d0cbc20bccb66dfed468501ac1688c0e4fb1",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731320773,
      "headline": "AbbVie Shares Slide, Bristol Myers Shares Rise After Schizophrenia Study Setback",
      "id": 131285465,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "By Colin Kellaher AbbVie said the schizophrenia drug candidate at the center of its recent $8.7 billion acquisition of Cerevel failed in a pair of mid-stage studies, sending the biopharmaceutical...",
      "url": "https://finnhub.io/api/news?id=5a697cc03be339764aacd9e391e2d0cbc20bccb66dfed468501ac1688c0e4fb1"
    }
  },
  {
    "ts": null,
    "headline": "Trending : AbbVie Schizophrenia Drug Fails in Mid-Stage Studies",
    "summary": "10:01 ET -- AbbVie is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. The biopharmaceutical company said its recently acquired...",
    "url": "https://finnhub.io/api/news?id=ca7edbc2c840791f34093e325b8e04685112f790654b76cd37c871e4b1b85326",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731320228,
      "headline": "Trending : AbbVie Schizophrenia Drug Fails in Mid-Stage Studies",
      "id": 131285319,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "10:01 ET -- AbbVie is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. The biopharmaceutical company said its recently acquired...",
      "url": "https://finnhub.io/api/news?id=ca7edbc2c840791f34093e325b8e04685112f790654b76cd37c871e4b1b85326"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie: falls on schizophrenia failure",
    "summary": "AbbVie is down 12% in early trading on Wall Street, after announcing the failure of its two Phase 2 trials EMPOWER-1 and 2, evaluating emraclidine in adults with schizophrenia who present an acute...",
    "url": "https://finnhub.io/api/news?id=7f985532e612251fc4ec8ce4dd6ab610a90761a232389ce8928c592ab91b1273",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731319224,
      "headline": "AbbVie: falls on schizophrenia failure",
      "id": 131285208,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "AbbVie is down 12% in early trading on Wall Street, after announcing the failure of its two Phase 2 trials EMPOWER-1 and 2, evaluating emraclidine in adults with schizophrenia who present an acute...",
      "url": "https://finnhub.io/api/news?id=7f985532e612251fc4ec8ce4dd6ab610a90761a232389ce8928c592ab91b1273"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Shares Fall Premarket After Schizophrenia Drug Study Failure -- Update",
    "summary": "By Colin Kellaher AbbVie said its recently acquired emraclidine drug candidate for schizophrenia missed the key goal in a pair of mid-stage studies, sending the biopharmaceutical company's shares...",
    "url": "https://finnhub.io/api/news?id=0863e5790fc9bd335721d3c80cd3982409320113b8f1b872c62d1de6456f44b9",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731318017,
      "headline": "AbbVie Shares Fall Premarket After Schizophrenia Drug Study Failure -- Update",
      "id": 131285040,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "By Colin Kellaher AbbVie said its recently acquired emraclidine drug candidate for schizophrenia missed the key goal in a pair of mid-stage studies, sending the biopharmaceutical company's shares...",
      "url": "https://finnhub.io/api/news?id=0863e5790fc9bd335721d3c80cd3982409320113b8f1b872c62d1de6456f44b9"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Shares Fall Premarket After Schizophrenia Drug Study Failure",
    "summary": "By Colin Kellaher AbbVie said its recently acquired emraclidine drug candidate for schizophrenia missed the key goal in a pair of mid-stage studies, sending the biopharmaceutical company's shares...",
    "url": "https://finnhub.io/api/news?id=2dbe519007e172aa2f2a9eff7ed47c9288b00a2c94f0da145fbef541e724255d",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731316337,
      "headline": "AbbVie Shares Fall Premarket After Schizophrenia Drug Study Failure",
      "id": 131284745,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "By Colin Kellaher AbbVie said its recently acquired emraclidine drug candidate for schizophrenia missed the key goal in a pair of mid-stage studies, sending the biopharmaceutical company's shares...",
      "url": "https://finnhub.io/api/news?id=2dbe519007e172aa2f2a9eff7ed47c9288b00a2c94f0da145fbef541e724255d"
    }
  }
]